Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences